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Abstract
Background: Multimorbidity is a major challenge for healthcare systems. However, currently, its magnitude and impact in
healthcare expenditures is still mostly unknown.
Objective: To present an overview of the prevalence and costs of multimorbidity by socioeconomic levels in the whole
Basque population.
Methods: We develop a cross-sectional analysis that includes all the inhabitants of the Basque Country (N = 2,262,698). We
utilize data from primary health care electronic medical records, hospital admissions, and outpatient care databases,
corresponding to a 4 year period. Multimorbidity was defined as the presence of two or more chronic diseases out of a list
of 52 of the most important and common chronic conditions given in the literature. We also use socioeconomic and
demographic variables such as age, sex, individual healthcare cost, and deprivation level. Predicted adjusted costs were
obtained by log-gamma regression models.
Results: Multimorbidity of chronic diseases was found among 23.61% of the total Basque population and among 66.13% of
those older than 65 years. Multimorbid patients account for 63.55% of total healthcare expenditures. Prevalence of
multimorbidity is higher in the most deprived areas for all age and sex groups. The annual cost of healthcare per patient
generated for any chronic disease depends on the number of coexisting comorbidities, and varies from 637 J for the first
pathology in average to 1,657 J for the ninth one.
Conclusion: Multimorbidity is very common for the Basque population and its prevalence rises in age, and unfavourable
socioeconomic environment. The costs of care for chronic patients with several conditions cannot be described as the sum
of their individual pathologies in average. They usually increase dramatically according to the number of comorbidities.
Given the ageing population, multimorbidity and its consequences should be taken into account in healthcare policy, the
organization of care and medical research.
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Introduction
Most OECD countries face major challenges in (re-)organising
the funding and provision of care to respond to the increasing
demands of patients with chronic diseases. Notably, most of those
patients suffer more than one chronic condition at the same time
and become multimorbid patients [1]. In fact, it has been
suggested that multimorbidity itself is the ‘‘most prevalent chronic
condition’’ [2],[3]. Individuals manifesting multimorbidities typi-
cally have a lower quality of life, and higher degree of disability,
psychological distress, risk of mortality, and utilisation of health
(and social) services than if we considered their chronic conditions
in isolation or individuals with a single chronic condition [4].
Therefore, it is widely accepted that health systems need to focus
their strategies for confronting such problem.
Although most studies on this topic refer to the re-organisation
of provision [5], [6], the economic impact is a major concern given
the concentration of health expenditures on these patients [7].
This health policy challenge is particularly important in countries
where there is a significant proportion of public funding, and even
more so in regions affected by the current poor economic situation
and outlook, including Spain. In these countries, public policy
makers find themselves involved in an urgent search for efficiency
in provision while still guaranteeing quality with equity in access,
in many systems in the context of universal coverage.
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The relationship between individual healthcare expenditures
and demographic characteristics and/or morbidity has been
extensively explored [8]. Nevertheless, the real impact that
individuals with multimorbidity have (and will have in the near
future) on healthcare costs and on the organization and
management of healthcare provision and financing is yet to be
seen and only recently a few authors have addressed this topic
from an empirical perspective [9]. Among those who have, some
have found a nearly linear relationship between increases in the
number of chronic conditions and individual’s healthcare costs
[10], [11], while others provide evidence of an exponential rise in
costs for patients with multimorbidity [12]. In this paper, we aim
to contribute to this niche in the literature [4], [13].
We exploit a unique database from the Basque Country, a
region in Spain, to look together at multimorbidity, healthcare
expenditures, and socioeconomic characteristics. In this way, we
present an analysis of the state of the art in the Basque Country
with respect to its health provision and planning, describe health
expenditures, and identify the real role and importance of
multimorbidity in the concentration of healthcare costs. Given
the similarities between the Basque population and the society and
demographics of most economically developed countries, our
insights into what we have learned in the Basque Country may be
extrapolated to other populations.
The objectives of this study are, first, to describe the map of
prevalence of chronic conditions and multimorbidity in the Basque
population; second, to observe that prevalence in socioeconomic
groups defined by a deprivation index [DI]; third, to present the
level of health expenditures on different types of healthcare
provision by individuals controlling for the presence of multi-
morbidity and deprivation.
Methods
This study utilized the database prepared by the population
stratification programme (PREST) of the Basque Country. Such
database is property of the Basque Health Service and the access
to it is restricted. The study population included every individual
covered on 31 August 2011 by the public health insurance in the
Basque Country and who had been covered for at least 6 months
in the previous year, regardless of whether they had made any
contact with or use of the Basque Health Service or not. That is,
practically all the inhabitants of the Basque Country are included.
Diagnoses on hospital discharge forms, emergency department
databases and primary care medical records are coded according
to ICD-9-CM [14], while the ATC [15] coding system is used for
drugs prescribed by primary care doctors. With this information,
residents in the Basque Country are classified annually using
ACGs [16]. Demographic variables including age on the final day
of the study period, and gender, were collected, along with the
area-based DI, chronic diseases recorded and yearly health costs.
The total population considered in the study is 2,262,707, of
which 50.90% are female. As for the age distribution, 15% of
patients are children (age ,18) and 20% are over 65.
Ethical Statement
The Clinical Research Ethics Committee of the Basque
Country approved this study according to the Spanish Law
14/2007 on Biomedical Research, the Ethical Principles for
Medical Research of the Declaration of Helsinki and other
applicable ethical principles. We used databases that employ an
opaque identifier to ensure patient confidentiality. Written consent
by the patients was specifically waived by the approving
Committee.
Setting
The Basque Country is one of the Spanish autonomous regions
with longest experience (since 1983) in managing competences in
health planning and provision and a pioneer in the transition
towards a chronic care model in Spain [17], [18]. In 2010 the
Department of Health and Consumer Affairs of the Autonomous
Region of the Basque Country launched its ‘‘Strategy for tackling
the challenge of chronicity in the Basque Country’’ [19]. This
strategy outlines the key guiding principles to improve the
responsiveness of the Basque healthcare system to chronic patients’
demands and thereby to enhance its efficiency and long-term
financial sustainability, as well as the quality of care for chronic
patients.
An important component of the strategy is to develop a tool for
the risk stratification of the entire population of the Basque
Country. For this purpose, a large dataset was assembled
combining information on individuals from several sources
(namely, primary and specialized health care records, and census
data) and including clinical - and utilisation data (e.g., diagnoses,
prescriptions, categorization of people according to their disease
burden by means of the Adjusted Clinical Groups case-mix system
[ACG] [16], [20], healthcare costs and an area-based DI).
The Basque Health System (Osakidetza) is an organization
publicly funded through general taxes. It provides universal
coverage to the citizens in the Basque Country. At the point of
delivery, provision of care is free of charge, with the exception of
pharmaceuticals, which can entail a co-payment. The percentage
charged varies according to the type of illness, the level of income
of the patient and his/her age.
Chronic Conditions and the Compilation of Data
Our study draws on various sources of information, and this
helps to overcome some of the shortcomings of using any of them
separately. In organizations such ours, where every resident is
registered on the list of a GP who acts as a gatekeeper for other
levels of care, primary care records are considered a reliable guide
to the prevalence of chronic illnesses. However, the extent to
which the records of diagnoses are complete is influenced by a
range of factors [21],[22],[23] and their combined use with
inpatient and outpatient specialised care can produce more
accurate estimates [24]. On the other hand, prescriptions records
can provide adequate information to identify patients with some
conditions [25], [26]. However, an exhaustive process of data
capture may lead to overestimation, detecting illnesses that are
long-lasting, but not currently active. In a recent study, Barnett et
al. (2012) developed a mixed method to identify 40 chronic
diseases [27], establishing specific criteria for each; depending on
the characteristics of the pathology, in some cases an isolated
diagnosis is accepted, in others prescriptions, diagnosis plus
prescriptions in the last year or a given number of prescriptions
are required.
In the present study, we considered four years of data for each
of the individuals in the Basque Country. Taking advantage of and
adapting the aforementioned methodology [27], we developed a
list of 52 health conditions and defined a specific criterion for each
to consider it active. A description of this process is included as
supporting material (File S1). For the purposes of the study,
multimorbidity was defined as the coexistence of two or more of
these conditions in the same patient.
Healthcare Costs
For the period between 1 September 2010 and 31 August 2011,
we estimated healthcare costs of primary care prescriptions
recorded in electronic health records based on the market value
Multimorbidity by Deprivation Level Basque Country
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of the drugs. For other variables (e.g., visits to Accident &
Emergency [A&E], rehabilitation sessions, outpatient care,
primary care visits, laboratory tests and radiological examinations
ordered by primary care, and various outpatient procedures such
as dialysis, radiotherapy and chemotherapy), the number of
services used by each patient was multiplied by standardized costs
(the average cost of each service provided to a patient treated in
Osakidetza, according to calculations made by the aforementioned
organisation). The costs of hospitalisation and outpatient surgery
were calculated in relation to their cost-weights in the correspond-
ing diagnosis-related groups (DRGs). Some services for which it
was not possible to obtain information were excluded; these
include admission to psychiatric hospitals, home care and day care
services (except for the procedures mentioned above), transporta-
tion, and prostheses and other equipment provided to patients at
home.
Socioeconomic Information
The DI, defined by census tract, was used as a socioeconomic
indicator. This index is an ordinal variable, categorized into five
levels (DI quintiles), providing a measure of the socioeconomic
characteristics of the population of census tracts. The DI was
elaborated and published in 2008. Its design allows for the
estimation of socioeconomic and environmental inequalities
among inhabitants by censal code in Spain. Its calculus takes into
account the percentages of residents who are manual workers,
unemployed, temporary employees, or have an inadequate level of
educational attainment, overall and also specifically among young
people [28], given the most recent Census (2001) available.
Statistical Analysis
Tables 1–7 present the descriptive statistics of our data. In order
to compare healthcare cost for individuals belonging to the
different categories of the DI given their number of chronic
conditions, we utilize the Kruskal-Wallis non-parametric test.
We use the Generalized Linear Model (GLM) with gamma
distribution and log link [29] to evaluate the relationship between
the number of chronic conditions and cost after adjusting for
confounding factors. As Healthcare cost data are typically non-
normally distributed with a skew towards the right, Gamma
regression is a better modeling approach to deal with this skewness
than Ordinary Least Square (OLS) regression [30], [31], [32]). In
our model, individual total cost was our dependent variable. The
independent variables we use were sex, age (by groups), DI, and
the number of chronic conditions. Given that age groups behave
differently of males and females in terms of the utilization of health
services and its cost, we also allowed for the interaction of age and
sex. Predicted mean adjusted costs were obtained by using the
recycled predictions methodology [33], [34]. This method
calculates the mean adjusted cost for each category in the variable
of interest as the average of all individual predictions based on the
regression model when all subjects are assigned to such category,
while holding constant all other model covariates.
Given that our goal is to observe the relationship between the
increase in individual cost and the number of chronic conditions,
we chose, by consensus within the research team, 10 among the
most common pathologies and whose cost is more significant. At
the same time, our methodology allows us to show how the
increase in individual cost is related to the characteristics of
specific pathologies. Hence, we run a log-gamma model separately
for each pathology using as independent variables age, sex, DI, the
number of other pathologies suffered by the patient, and the
interaction of each pathology with the number of other
pathologies. Out of those estimation models, we obtain the mean
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adjusted cost (by recycled predictions methods) and analyze
whether they vary when the number of comorbidities increases.
All this analysis was performed using SAS (version 9.2).
Results
Prevalence of Multimorbidity
Table 1 shows the distribution of the population by age group as
well as the average number of chronic diseases per patient, this
being 0.97 overall. The percentage of the population with
multimorbidity is 23.61%, representing 55% of patients with any
chronic condition, given that 42.92% have at least one chronic
condition (as shown in Table 2).
Chronic conditions are more common in females than in males,
and their prevalence rises with age up to 85 years old, when there
is a slight decrease. Multimorbidity affects more than half of the
population over 65 and more than three quarters of those between
80 and 84 years old.
Multimorbidity and Socioeconomic Status
Those with a greater number of illnesses tended to live in more
deprived areas. This pattern is seen in both sexes and all age
groups. When comparing the most and least deprived groups, the
differences are larger, in relative terms, at younger ages and
somewhat less so in the older groups (Table 1).
Concentration of Health Expenditures in Multimorbid
Patients
Table 2 shows the percentage of healthcare spending by
number of chronic diseases. Chronic patients (42.92% of the
population) are responsible for 80.57% of total healthcare
expenditures (86.71% for inpatient care and 95.16% for prescrip-
tions). Importantly, even in the case of A&E, spending on chronic
patients represents more than half of the total (55.42%). The
concentration of health expenditures is evidenced by the fact that
23.61% of patients have multiple conditions (multimorbidity
according to the definition used for this study) but they account
for 63.55% of total healthcare expenditures. Of those, patients
with five of more chronic conditions, representing less than 5% of
the population (4.33%), consume almost a quarter of the total
healthcare resources (24.65%).
Health Expenditures and Socioeconomic Status
The average cost of the healthcare provided for each patient
was J1,124. Tables 3–7 show the median, 25th and 75th percentile
of costs as a function of number of chronic conditions and DI.
Table 3. Comparison of medians of annual primary care costs per patient, depending on number of chronic diseases and
deprivation index.
PRIMARY CARE COST: median (percentile 25th–75th)
No, Chronic
conditions Deprivation Index All
1 2 3 4 5
0 37 J (0–150) 74 J (0–189) 74 J (0–204) 74 J (0–202) 74 J (0–215) 74 J (0–189) *
1–3 267 J (137–447) 296 J (150–479) 302 J (152–491) 316 J (165–506) 317 J (167–509) 300 J (150–486) *
4–6 562 J (360–845) 606 J (401–892) 623 J (412–903) 630 J (418–911) 623 J (417–899) 611 J (402–892) *
7–9 861 J (558–1264) 898 J (589–1318) 946 J (634–1361) 924 J (621–1301) 923 J (632–1290) 912 J (610–1304) *
10+ 1,225 J (861–1803) 1,303 J (883–1817) 1,252 J (832–1818) 1,268 J (913–1758) 1,283 J (885–1774) 1,264 J (872–1790) #
All 113 J (0–313) 152 J (37–365) 176 J (37–387) 185 J (37–406) 189 J (37–417) 163 J (37–376) *
*p,0.001;
#non-significant.
doi:10.1371/journal.pone.0089787.t003
Table 4. Comparison of medians of annual specialised care costs per patient, depending on number of chronic diseases and
deprivation index.
SPECIALISED CARE COST without hospitalization, but including A&E: median (percentile 25th–75th)
No, Chronic
conditions Deprivation Index All
1 2 3 4 5
0 0 J (0–153) 0 J (0–164) 0 J (0–164) 0 J (0–164) 0 J (0–164) 0 J (0–164) *
1–3 164 J (0–410) 164 J (0–484) 164 J (0–492) 164 J (0–492) 246 J (0–563) 164 J (0–492) *
4–6 410 J (153–891) 481 J (164–973) 492 J (164–1019) 552 J (235–1044) 563 J (246–1055) 492 J (164–984) *
7–9 727 J (317–1372) 820 J (399–1493) 820 J (410–1535) 891 J (410–1596) 891 J (481–1607) 820 J (410–1535) *
10+ 1,214 J (634–2235) 1,225 J (645–2077) 1,279 J (705–2018) 1,307 J (727–2144) 1,285 J (705–2160) 1,278 J (694–2122) #
All 0 J (0–246) 82 J (0–328) 82 J (0–328) 82 J (0–399) 153 J (0–410) 82 J (0–328) *
*p,0.001;
#non-significant.
doi:10.1371/journal.pone.0089787.t004
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According to these indicators, the total healthcare cost per person
is slightly higher in more deprived social areas. The same trend is
seen comparing the figures of the groups of patients with different
numbers of chronic diseases. Those differences are statistically
significant (p,0.001) for all different categories of health
expenditure, both for the general population and for each specific
group of multimorbid patients, but for those individuals with 10 or
more pathologies, where only the difference in expenditures in
pharmaceutical prescriptions is statistically significant (p,0.05).
Regression Analisis: Relationships between Health
Expenditures and Number of Chronic Diseases
We present the results from the Generalized Linear Model
(GLM) with gamma distribution in the supporting material (table
B in File S2). From those estimations we have obtained the average
individual cost adjusted by the independent variables age, sex DI
and number of pathologies, as shown in tables 8 and 9.
Once adjusted per number of chronic conditions and socioeco-
nomic characteristics, the effect of ageing is small. Furthermore,
individual cost for children (with an equal number of diseases) is
greater than for other ranges of age. With respect to age,
individual cost for females is lower than for males for all ages but in
the range of 18–44 years old, as expected due to obstetric care.
We also analyze the effect of socioeconomic status through the
DI. The average individual cost for those in the most deprived
socioeconomic group is significantly (25%) higher than that of
individuals in the most favorable socioeconomic group.
The increase in healthcare expenditures observed in the
number of chronic diseases is shown in Table 9. The annual
average cost for patients with one chronic disease is J637 higher
than that for people with none, while the effect of ‘‘adding’’ a
second, third or fourth disease becomes progressively more
expensive and, for example, the cost of another illness after the
eighth rises to an additional J 1,657 per year.
Health Expenditures for Patients with Specific Conditions
In our analysis, we find that it is not only the number of chronic
diseases what matters when looking at the increase in cost, but also
which are the conditions suffered by patients and specifically,
which is the considered primary condition. Table 10 and figure 1
present average costs by coexistence of other conditions for some
specific health conditions. On the one hand, for chronic
obstructive pulmonary disease (COPD), diabetes mellitus, ischae-
mic heart disease and heart failure there are progressive increases
according to the number of other coexisting conditions (there
being a two- to three-fold difference between the annual cost of
patients with and without any of these four conditions, in the case
of patients with another eight conditions). On the other hand, the
reverse is true in the cases of depression or anxiety, greater
comorbidity leading to progressively smaller rises and even
negative differences for comorbidity of seven or more chronic
diseases, and malignancies or cerebrovascular disease, with costs
rising up to a point (other six diseases) and falling afterwards.
Discussion
In this paper, we utilize a unique database on the entire
population of the Basque Country. The Basque Country being a
region in Spain, its size in terms of population, more than two
million people, is similar to that from small countries in Europe
like Lithuania, Slovenia or Latvia, and only half of the population
than countries as Norway, Ireland or Croatia, being greater than
almost half of the States in the US. The uniqueness of our data set
-with respect to related articles in the literature-, consists in it
containing four years of individual -clinical and cost- data from
different sources of information to cover a great proportion of the
public resources used, for the entire population of the Basque
Country, as well as an indicator of socioeconomic status. Hence,
we avoid the potential biases of taking into account only a
proportion of the population (such as the elderly), one type of
healthcare service provision (such as primary care), or using
information only from some selected health centres.
We show evidence of how multimorbidity is a common
phenomenon and its presence increases with the age of the
population considered, and of the concentration of healthcare
expenditures in patients with multimorbidity). Together with the
process of ageing in the population, common to all developed
countries, our results add to the body of evidence justifying the
great international concern about public health provision,
Table 5. Comparison of medians of prescriptions costs per patient, depending on number of chronic diseases and deprivation
index.
PRESCRIPTIONS: median (percentile 25th–75th)
No,
Chronic
conditions Deprivation Index All
1 2 3 4 5
0 0 J (0–4) 0 J (0–8) 0 J (0–9) 0 J (0–10) 0 J (0–10) 0 J (0–8) *
1–3 70 J (6–319) 66 J (8–295) 65 J (8–292) 70 J (10–305) 65 J (9–293) 67 J (8–301) *
4–6 626 J (269–
1183)
643 J (283–1217) 645 J (285–1209) 650 J (287–1240) 646 J (277–1231) 642 J (281–1217) *
7–9 1,118 J (579–
1863)
1,184 J (611–1959) 1,202 J (640–1985) 1,204 J (654–1993) 1,186 J (612–1978) 1,180 J (623–1959) *
10+ 1,509 J (778–
2446)
1,639 J (923–2528) 1,686 J (933–2599) 1,627 J (970–2588) 1,612 J (944–2552) 1,612 J (921–2557) **
All 2 J (0–61) 6 J (0–77) 8 J (0–88) 10 J (0–110) 10 J (0–106) 7 J (0–87) *
*p,0.001;
**p,0,05.
doi:10.1371/journal.pone.0089787.t005
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planning, and funding for patients with multimorbidity in the near
future. Furthermore, there are two respects in which the Basque
Country is ahead of other regions and countries in the need for
efficiency in health provision, making these findings particularly
relevant for the international audience. First, the population in the
Basque Country is already slightly more aged than that of Spain as
a whole [35], one of the most aged developed countries. Second,
the current economic conditions in Spain produces a sense of
urgency among policy makers and is resulting in numerous
implementations of policies promoting direct and indirect cuts in
health expenditures [36].
An innovative pillar of our analysis is to include a socioeco-
nomic indicator and explore its relationship with the prevalence
and healthcare expenditures of patients with multimorbidity. We
show evidence that both the prevalence of multimorbidity and
thus the level of need in provision, are greater in more deprived
geographical areas. In the Basque Country, there is no evidence of
inequity (or discrimination against populations in more deprived
areas) as the greater the need, the greater the level of public health
expenditures. This reflects decades of planning and development
of primary care services in the National Health Service. However,
the greater prevalence of multimorbid patients in more deprived
areas is of public concern in itself and should be taken into account
as a gradient between health and wealth.
We also find evidence of how, on average, the annual use of
healthcare resources by chronically ill patients grows as the
number of chronic diseases increases. Notably, our data suggests
that this increase is not linear but rather tends to be progressive.
This is the most common pattern and, it would seem, the most
expected for the prevalence of all chronic conditions. There are
exceptions, however, namely depression and anxiety: patients with
either of these conditions and more than five (in the case of
depression) or two (in the case of anxiety) other chronic diseases,
use a lower level of resources than if they only had these other
chronic health problems. In other conditions, such as malignant
neoplasms or cerebrovascular disease, healthcare costs increase
progressively with multimorbidity, the magnitude of the increase
growing for up to six more diseases but falling thereafter. That
result, although initially paradoxical, might be explained through
different interpretations. Patients with some of those chronic
conditions (as mental condition) might be reluctant to look for or
might find more obstacles to access health service provision than
individuals without those conditions. Also, clinical records for
patients with multiple diseases and the elderly can be particularly
difficult [37] and therefore, their diagnoses are less accurate.
Hence, physicians may not record a diagnosis of anxiety or
depression when there seems to be a clear reason for it. At the
same time, it is also plausible that in the case of some especially
severe conditions, as malignancies, treatments tend to be more
aggressive for patients with less comorbidities than in those, more
complex patients, with a greater combination of chronic problems.
Lastly, although we do account for the number of chronic diseases
and which conditions are those, we have no information on their
level of severity, and for each specific case, some might be more
severe than others.
We have shown how in the Basque Country health expenditures
are concentrated in patients with multimorbidity, and within this
group, the most expensive are those with heart failure, ischaemic
heart disease, and diabetes mellitus among other conditions.
Having identified the most expensive populations in terms of
public health expenditures, the next step is to design strategies and
undertake proactive interventions specifically for those patients.
The aforementioned ‘‘Strategy for tackling the challenge of
chronicity in the Basque Country’’ [19], launched in 2010,
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already encouraged changes in this direction. Our most recent
results, however, underline the need to keep making further efforts
in the re-organisation of health provision specifically for the
patients identified, who are those that will benefit the most from
increasing care coordination. In this area, integrated care
approaches for patients with multiple conditions are increasingly
popular in Spain and preliminary evaluations seem promising in
terms of their effectiveness [38].
The goal is to improve the level of control of the relevant
indicators for patients identified as being most in-need or at-risk,
e.g., those that are most expensive, are readmitted most frequently
or fulfil various clinical criteria [39], [40].
Our study has certain limitations. Firstly, administrative
databases obviously only contain information about health
problems for which people seek medical care. Therefore, the
prevalence of diseases only reflects attended morbidity excluding
conditions that might be present but have not yet manifested or
have not been detected by either the patients or their doctors. This
is quite common in chronic diseases and it is influenced by various
factors, such as accessibility to healthcare services, though this is
not questioned in our setting for the case of the Basque Health
Service. Secondly, our database does not contain information on
psychiatric hospitals; and, even though patients admitted in such
hospitals are also usually cared for by primary care doctors, given
their special characteristics, it is possible that their health records
were not as complete as for the rest of the population. Thirdly,
employing socioeconomic indicators at the level of area of
residence, our study has the limitations common to ecological
studies. Finally, cost data are restricted to expenditures funded by
Table 7. Comparison of medians of total health care costs per patient, depending on number of chronic diseases and deprivation
index.
TOTAL COST: median (percentile 25th–75th)
No,
Chronic
conditions Deprivation Index All
1 2 3 4 5
0 82 J (0–324) 147 J (0–405) 153 J (0–426) 153 J (0–424) 162 J (0–465) 139 J (0–404) *
1–3 682 J (320–1312) 724 J (345–1397) 743 J (356–1443) 780 J (377–1498) 799 J (384–1543) 744 J (355–1437) *
4–6 2,108 J (1242–4100) 2,278 J (1348–4433) 2,302 J (1376–4545) 2,391 J (1433–4709) 2,414 J (1433–4753) 2,303 J (1369–4535) *
7–9 4,461 J (2440–9341) 5,097 J (2720–10450) 5,143 J (2819–10549) 5,207 J (2832–10701) 5,172 J (2820–10450) 5,048 J (2734–10349) *
10+ 10,275 J (5210–20071) 10,280 J (4960–19189) 10,331 J (5341–18544) 10,178 J (5270–18380) 9,956 J (5011–18653) 10,212 J (5130–18767) #
All 261 J (26–798) 342 J (68–939) 373 J (77–1011) 402 J (82–1096) 431 J (93–1149) 356 J (65–988) *
*p,0.001;
#non-significant.
doi:10.1371/journal.pone.0089787.t007
Table 8. Healthcare expenditure.
Age Group Male Female
00–04 2,550 2,316
05–11 1,125 1,057
12–17 933 859
18–34 798 1,298
35–44 818 1,300
45–54 921 1,033
55–64 1,098 1,083
65–69 1,231 1,156
70–74 1,262 1,187
75–79 1,303 1,209
80–84 1,254 1,161
85+ 1,078 1,030
Means, adjusted by generalized linear regression model, of several groups of
population.
doi:10.1371/journal.pone.0089787.t008
Table 9. Healthcare expenditure.
Deprivation Index 1 976
2 1,117
5 1,155
4 1,186
5 1,226
Number of Chronic Diseases 0 380
1 1,017
2 1,735
3 2,533
4 3,406
5 4,506
6 5,799
7 7,348
8 8,759
9 10,417
10+ 13,891
Means, adjusted by generalized linear regression model, of several groups of
population.
doi:10.1371/journal.pone.0089787.t009
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the public sector, and individual health care costs were calculated
from the standard pricing of the services provided, with the
exception of drug costs (based on their market value) and DRGs
(average costs from cost accounting). That is, certain costs have not
been considered, namely the costs of activities not included in the
dataset, e.g., admissions to mental health hospitals, home
hospitalisation, etc. (we estimate that 21.58% of the total cost is
not included in our analysis). We interpret the lack of data on use
and costs in private health centres as a plausible explanation for
the greater need (and higher demand) for outpatient services from
more deprived socioeconomic areas. However, even if that were to
be true, the fact that hospitalisation is similar for all socioeconomic
groups demonstrates the trust of the entire population in the public
provision under the national health service for expensive
treatments and maybe some adverse selection in the private
health insurance market. Further, this paper is focused on the
organisation of public health service provision and planning, and
thus, private health provision is beyond the scope of our analysis.
At the same time, the fact that some health expenditures are
derived from cost standardisation might explain the lower
concentration of health expenditures in the most expensive
patients compared to other studies in the literature, given that
the level of prices (unit cost) is in Spain lower than in that in other
countries.
In essence, multimorbidity occurs as a complex phenomenon
and patients with multiple health problems do not share a
common set of characteristics. It is known that the relationship
between comorbidity, quality and healthcare outcomes is not
uniform, and depends upon the specific combination of diseases
[3]. Future studies are needed to determine whether the observed
higher expenditures among multimobid patients are justified or
not, in order to detect possible inefficiencies in their care. Besides,
further research is required to characterize the diverse subgroups
of patients with multimorbidity, to implement specific, patient-
centred care programmes.
Conclusions
Multimorbidity is a very common finding, its prevalence rises
with age, and it is related to unfavourable socioeconomic factors.
The costs of caring for chronic patients tend to increase
dramatically with the number and combination of comorbidities,
although the pattern varies for certain specific diseases. Our paper
using comprehensive data on the utilization of all levels of public
health services by the entire population of the Basque Country
shows the burden of multimorbidity in a population engaged in an
irreversible process of population ageing and the implications of
multimorbidity for patients. Moreover, the current economic crisis
has pushed the Basque Country, in search of efficiency, to
innovate in the study of multimorbidity and its effect in patients,
families and caregivers. This is perhaps the most important current
challenge for policy makers, administrators, clinicians, and
researchers in our health system, and probably also in that of
Figure 1. Difference in average of adjusted annual cost (in euros) per patient, by number of coexisting chronic diseases according
to the presence of certain selected diseases.
doi:10.1371/journal.pone.0089787.g001
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other developed countries, to guarantee the quality of care
provided.
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